The purpose of this study is to determine if nimodipine is more effective than placebo in reducing stimulated craving for cocaine in cocaine dependent individuals denied access to cocaine in inpatient unit...
Date First Received: September 20, 1999
Last Updated: June 23, 2005
Verified by: National Institute on Drug Abuse (NIDA), December 2002
Clinical Trial Phase: Phase 2 | Start Date:
Overall Status: Completed
Estimated Enrollment: 0
Brief Summary
Official Title: “High Dose Nimodipine Pharmacotherapy Adjunct”
Condition Keyword(s):
Intervention(s):
The purpose of this study is to determine if nimodipine is more effective than placebo in reducing stimulated craving for cocaine in cocaine dependent individuals denied access to cocaine in inpatient unit.
Study Type: Interventional
Study Design: Treatment
Intervention(s) in this Clinical Trial
- Drug: Nimodipine
Outcome Measures for this Clinical Trial
Primary Measures
- Stimulated and non-stimulated craving
- Stimulated and non-stimulated withdrawal
- Anxiety, depression
- Heart rate
Criteria for Participation in this Clinical Trial
- Please contact site for information.
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 22 Years
Maximum Age for this Clinical Trial: 45 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: National Institute on Drug Abuse (NIDA)
Overall Clinical Trial Officials and Contacts
Steven Deutsch, M.D. Principal Investigator Washington DC VA
Additional Information
Information obtained from ClinicalTrials.gov on August 28, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00000332
Study ID Number: NIDA-3-0009-1
ClinicalTrials.gov Identifier: NCT00000332
Health Authority: United States: Federal Government
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
